KR101563069B1 - 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 - Google Patents

다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 Download PDF

Info

Publication number
KR101563069B1
KR101563069B1 KR1020137023170A KR20137023170A KR101563069B1 KR 101563069 B1 KR101563069 B1 KR 101563069B1 KR 1020137023170 A KR1020137023170 A KR 1020137023170A KR 20137023170 A KR20137023170 A KR 20137023170A KR 101563069 B1 KR101563069 B1 KR 101563069B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
treatment
acceptable salt
temozolomide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137023170A
Other languages
English (en)
Korean (ko)
Other versions
KR20130118981A (ko
Inventor
우르스 레게나스
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45787254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101563069(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20130118981A publication Critical patent/KR20130118981A/ko
Application granted granted Critical
Publication of KR101563069B1 publication Critical patent/KR101563069B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137023170A 2011-02-04 2012-02-03 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 Expired - Fee Related KR101563069B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2011/050494 2011-02-04
IB2011050494 2011-02-04
PCT/IB2012/050513 WO2012104822A1 (en) 2011-02-04 2012-02-03 Combinations comprising macitentan for the treatment of glioblastoma multiforme

Publications (2)

Publication Number Publication Date
KR20130118981A KR20130118981A (ko) 2013-10-30
KR101563069B1 true KR101563069B1 (ko) 2015-10-23

Family

ID=45787254

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137023170A Expired - Fee Related KR101563069B1 (ko) 2011-02-04 2012-02-03 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물

Country Status (21)

Country Link
US (1) US20130310407A1 (enExample)
EP (2) EP2965757A1 (enExample)
JP (2) JP5642892B2 (enExample)
KR (1) KR101563069B1 (enExample)
CN (1) CN103327975A (enExample)
AR (1) AR085132A1 (enExample)
AU (1) AU2012213036A1 (enExample)
BR (1) BR112013019680A2 (enExample)
CA (1) CA2823994A1 (enExample)
CL (1) CL2013002193A1 (enExample)
CO (1) CO6761366A2 (enExample)
EA (1) EA201391131A1 (enExample)
IL (1) IL227747A0 (enExample)
MA (1) MA34952B1 (enExample)
MX (1) MX2013008798A (enExample)
PH (1) PH12013501461A1 (enExample)
SG (1) SG192600A1 (enExample)
TN (1) TN2013000333A1 (enExample)
TW (1) TW201309298A (enExample)
WO (1) WO2012104822A1 (enExample)
ZA (1) ZA201306613B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
HRP20150890T1 (hr) 2009-08-10 2015-09-25 Board Of Regents, The University Of Texas System Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom
CN103397308A (zh) * 2013-08-01 2013-11-20 光垒光电科技（上海）有限公司 用于mocvd设备的喷淋头
TWI559928B (en) * 2014-08-20 2016-12-01 Academia Sinica Methods for enhancing permeability to blood-brain barrier and uses thereof
KR101701619B1 (ko) 2015-06-26 2017-02-01 건양대학교산학협력단 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물
KR102574253B1 (ko) 2020-12-15 2023-09-07 주식회사 시선테라퓨틱스 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물
CN115317604B (zh) * 2022-08-11 2023-09-22 南京脑科医院 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009104149A1 (en) 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0116237B8 (pt) 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2008111092A1 (en) * 2007-03-09 2008-09-18 Fresenius Kabi Oncology Limited Crystalline temozolomide monohydrate and process for preparation thereof
HRP20150890T1 (hr) * 2009-08-10 2015-09-25 Board Of Regents, The University Of Texas System Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009104149A1 (en) 2008-02-20 2009-08-27 Actelion Pharmaceuticals Ltd Combination comprising paclitaxel for treating ovarian cancer

Also Published As

Publication number Publication date
PH12013501461A1 (en) 2019-03-22
EP2670405B1 (en) 2015-09-02
US20130310407A1 (en) 2013-11-21
CL2013002193A1 (es) 2014-05-09
TN2013000333A1 (en) 2015-01-20
ZA201306613B (en) 2015-04-29
TW201309298A (zh) 2013-03-01
MA34952B1 (fr) 2014-03-01
IL227747A0 (en) 2013-09-30
CN103327975A (zh) 2013-09-25
EA201391131A1 (ru) 2013-12-30
CA2823994A1 (en) 2012-08-09
MX2013008798A (es) 2013-10-17
AU2012213036A1 (en) 2013-09-19
WO2012104822A1 (en) 2012-08-09
EP2965757A1 (en) 2016-01-13
SG192600A1 (en) 2013-09-30
CO6761366A2 (es) 2013-09-30
NZ615005A (en) 2015-10-30
EP2670405A1 (en) 2013-12-11
JP2015057409A (ja) 2015-03-26
JP5642892B2 (ja) 2014-12-17
JP2014504636A (ja) 2014-02-24
KR20130118981A (ko) 2013-10-30
AR085132A1 (es) 2013-09-11
BR112013019680A2 (pt) 2016-10-11

Similar Documents

Publication Publication Date Title
KR101563069B1 (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
CN107072991A (zh) 磷酸酶抑制剂的人类给药
JP2007525485A (ja) 複合的な放射線治療及び化学治療の組成物及び方法
JP2009542623A (ja) Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療
EA029072B1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
US20240325397A1 (en) Use of combination therapy for treating cancer
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
KR20240104138A (ko) 니로가세스타트를 사용한 조성물 및 치료
WO2021154976A1 (en) Methods of treating brain cancer with panobinostat
CN111629727A (zh) 用于治疗血液肿瘤和实体癌的钙释放活化钙通道调节剂
JP2009539774A (ja) 薬物の投与方法
NZ615005B2 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
WO2025255237A1 (en) Use of atr inhibitors in combination with radioligand therapy for the treatment of cancer
CN118338900A (zh) 含尼罗加司他的组合物和治疗
WO2024102968A1 (en) Uses of ep2/ep4 antagonist compounds for treating familial adenomatous polyposis (fap)
KR20220002745A (ko) 암 치료 방법 및 용도
EP1599210A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181020

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181020